The ‘FebBenz’ approach for severe difficult-to-treat gout

Abstract

Aim: To evaluate the efficacy and tolerability of febuxostat (FBX) and benzbromarone (BNZ) combination therapy in patients with difficult-to-treat (D2T) gout.

Methods: This observational study was performed at two centers and included patients fulfilling the 2015 European Alliance of Associations for Rheumatology/American College of Rheumatology (EULAR/ACR) gout classification criteria, with clinical tophi and suboptimal response to standard urate-lowering therapy. A two-step treatment regimen was implemented: a 6-month dose escalation of the FBX dose followed by add-on BNZ. Demographic, clinical, and laboratory data-including cardiovascular risk factors (CVRFs), history of nephrolithiasis, liver enzymes, and estimated glomerular filtration rate (eGFR)-were recorded. Changes in serum urate (SUA) and eGFR were analyzed using paired t-tests.

Results: The study population comprised 15 patients (87% male, median age 59 years) with longstanding gout [median 15 years, range 3–31; interquartile range (IQR) 8–25]. Baseline SUA was 10.3 ± 1.7 mg/dL; mean eGFR was 63.7 ± 23.6 mL/min. CVRFs were common (hypertension, 93%; dyslipidemia, 73%: major adverse cardiovascular events, 13%; diabetes, 7%). At 12 months, SUA had decreased significantly to 2.9 ± 1.1 mg/dL (Δ = 7.4 mg/dL; p < 0.01), with FBX alone contributing to a Δ of 5.4 mg/dL and BNZ an additional Δ of 2.1 mg/dL (both p < 0.01). Tophi resolved in 60% of patients. No serious adverse events or significant changes in liver or renal function were observed. One unrelated death was recorded.

Conclusions: FBX + BNZ was effective and well-tolerated in patients with severe D2T gout, achieving a substantial reduction in SUA and clinically significant dissolution of tophi.

Keywords

Gout / difficult-to-treat / uric acid / tophi / urate-lowering therapy / benzbromarone / febuxostat

References

[1] Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020; 16: 380-90.

[2] Jin Z, Feng X, Wang D, Zhu Y, Liang J, Zhang H, et al. Global, regional and national trends in sex- and age-specific disability-adjusted life years of musculoskeletal disorders, 1990-2019. Rheumatology (Oxford). 2022; 61: 2978-86.

[3] Cairns I, Lindsay K, Dalbeth N, Díaz-Torné C, Antònia Pou M, Rodríguez Diez B, et al. The impact of gout as described by patients, using the lens of The International Classification of Functioning, Disability and Health (ICF): a qualitative study. BMC Rheumatol. 2020; 4: 50.

[4] Kiltz U, Smolen J, Bardin T, Cohen Solal A, Dalbeth N, Doherty M, et al. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis. 2017; 76: 632-8.

[5] FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol. 2020; 72: 879-95.

[6] Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017; 76: 29-42.

[7] Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011; 306: 711-20.

[8] Pascual E, Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis. 2007; 66: 1056-8.

[9] Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002; 47: 356-60.

[10] Azevedo VF, Buiar PG, Giovanella LH, Severo CR, Carvalho M. Allopurinol, benzbromarone, or a combination in treating patients with gout: analysis of a series of outpatients. Int J Rheumatol. 2014; 2014: 263720.

[11] Ohno I, Okabe H, Yamaguchi Y, Saikawa H, Uetake D, Hikita M, et al. Usefulness of combination treatment using allopurinol and benzbromarone for gout and hyperuricemia accompanying renal dysfunction: kinetic analysis of oxypurinol. Nihon Jinzo Gakkai Shi. 2008; 50: 506-12.

[12] Maekawa M, Tomida H, Aoki T, Hishida M, Morinaga T, Tamai H. Successful treatment of refractory gout using combined therapy consisting of febuxostat and allopurinol in a patient with chronic renal failure. Intern Med. 2014; 53: 609-12.

[13] Xue X, Sun M, Yan F, Dalbeth N, He Y, Li X, et al. Superiority of Low-Dose Benzbromarone Add-On to Low-Dose Febuxostat Compared With Febuxostat Monotherapy in Gout With Combined-Type Hyperuricemia. Arthritis Care Res (Hoboken). 2024; 76: 703-11.

[14] Pascart T, Lefebvre A, Ducoulombier V, Becce F, Budzik JF. Drastic monosodium urate crystal dissolution with febuxostat and benzbromarone. Joint Bone Spine. 2021; 88: 105178.

[15] Pérez-Ruiz F, Jansen T, Tausche AK, Juárez-Campo M, Gurunath RK, Richette P. Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout. Drugs Context. 2019; 8: 212581.

[16] Dalbeth N, Doyle AJ, Billington K, Gamble GD, Tan P, Latto K, et al. Intensive Serum Urate Lowering With Oral Urate-Lowering Therapy for Erosive Gout: A Randomized Double-Blind Controlled Trial. Arthritis Rheumatol. 2022; 74: 1059-69.

[17] Löffler W, Fairbanks L, Gibson T. Treating gout - can hypouricemia produced by moderate doses of combined oral treatment give early treatment success? Preliminary observations. Nucleosides Nucleotides Nucleic Acids. 2022; 41: 1267-78.

[18] Kurajoh M, Koyama H, Hatayama M, Okazaki H, Shoji T, Moriwaki Y, et al. Partial HPRT Deficiency with a Novel Mutation of the HPRT Gene in Combination with Four Previously Reported Variants Associated with Hyperuricemia. Intern Med. 2015; 54: 1523-6.

[19] Reinders MK, van Roon EN, Houtman PM, Brouwers JR, Jansen TL. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clin Rheumatol. 2007; 26: 1459-65.

[20] Reinders MK, van Roon EN, Jansen TL, Delsing J, Griep EN, Hoekstra M, et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis. 2009; 68: 51-6.

[21] Pascart T, Norberciak L, Ea HK, Graf S, Guggenbuhl P, Lioté F. Difficult-to-treat gout flares: eligibility for interleukin-1 inhibition in private practice is uncommon according to current EMA approval. Rheumatology (Oxford). 2019; 58: 2181-7.

[22] Schlesinger N. Difficult-to-treat gouty arthritis: a disease warranting better management. Drugs. 2011; 71: 1413-39.

[23] Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012; 71: 1839-48.

[24] Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015; 74: 1789-98.

[25] Keenan RT, O’Brien WR, Lee KH, Crittenden DB, Fisher MC, Goldfarb DS, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011; 124: 155-63.

[26] Alvarado-de la Barrera C, López-López CO, Álvarez-Hernández E, Peláez-Ballestas I, Gómez-Ruiz C, Burgos-Vargas R, et al. Are Target Urate and Remission Possible in Severe Gout? A Five-year Cohort Study. J Rheumatol. 2020; 47: 132-9.

[27] Ankli B, Berger CT, Haeni N, Kyburz D, Hügle T, So AK, et al. The target uric acid level in multimorbid patients with gout is difficult to achieve: data from a longitudinal Swiss single-centre cohort. Swiss Med Wkly. 2019; 149: w20121.

[28] Calvo-Aranda E, Perez-Ruiz F. Towards a more ambitious uricemia target to improve joint and cardiovascular outcomes in gout. Explor Musculoskeletal Dis. 2023; 1: 20-5.

[29] Pérez Ruiz F, Richette P, Stack AG, Karra Gurunath R, García de Yébenes MJ, Carmona L. Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality. RMD Open. 2019; 5: e001015.

[30] Perez-Ruiz F, Martínez-Indart L, Carmona L, Herrero-Beites AM, Pijoan JI, Krishnan E. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2014; 73: 177-82.

[31] Ohta Y, Ishizuka A, Arima H, Hayashi S, Iwashima Y, Kishida M, et al. Effective uric acid-lowering treatment for hypertensive patients with hyperuricemia. Hypertens Res. 2017; 40: 259-63.

[32] Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008; 59: 1540-8.

[33] Schlesinger N, Pérez-Ruiz F, Lioté F. Mechanisms and rationale for uricase use in patients with gout. Nat Rev Rheumatol. 2023; 19: 640-9.